Clinical trials: BPH (Benign Prostatic Hyperplasia)
Benign Prostatic Hyperplasia
The Zenflow Spring System Safety and Performance Study (ZEST CAN)
The objectives of the trial are to demonstrate the safety and performance of the Zenflow Spring System in relieving the symptoms of obstructive Benign Prostatic Hyperplasia (BPH).
- Trial name
- NCT04309695
- Testing
- Zenflow Spring System
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Zenflow, Inc.
Benign Prostatic Hyperplasia (BPH)
REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men
The study objective is to compare water vapor thermotherapy with the REZŪM™ System to dual drug therapy for the treatment of symptomatic benign prostatic hyperplasia refractory to alpha-blocker monotherapy in sexually active men.
- Trial name
- VAPEUR (NCT04838769)
- Testing
- REZŪM, alpha blocker and 5-alpha reductase inhibitor
- Where
- 21 sites in Australia, France
- Volunteers
- 155 people
- Sponsor
- Boston Scientific Corporation
Prostate Cancer, Benign Prostatic Hyperplasia
Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
Emerging from a differential proteomic study of sample pairs of prostate cancer and benign tissue, annexin A3 (ANXA3) was chosen as a potential novel biomarker for the early and non-invasive diagnosis of prostate cancer.
- Conditions
- Prostate Cancer, Benign Prostatic Hyperplasia, Prostatic Intraepithelial Neoplasia
- Trial name
- NCT00400894
- Volunteers
- 750 people
- Sponsor
- ProteoSys AG
Prostate Disease, BPH
Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)
Multi-center, prospective randomized dosing and safety research study. A maximum of 150 men will be enrolled in the study. Qualifying patients will receive one of three possible doses of the study drug.
- Conditions
- Prostate Disease, BPH, Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy
- Trial name
- NCT00037141
- Testing
- dehydrated alcohol
- Volunteers
- 150 people
- Sponsor
- American Medical Systems
Prostatic Hyperplasia
WEUSKOP5723: Prostate Cancer Study
This retrospective cohort study will assess the association of benign prostatic hyperplasia (BPH) treatment (5-alpha reductase inhibitors (5ARI) and alpha-blocker medications) with the occurrence of prostate cancer related…
- Trial name
- NCT01767363
- Testing
- 5-alpha reductase inhibitors, Alpha-blockers
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
LUTS, Benign Prostatic Hyperplasia
Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 in Healthy Male Volunteers
The purpose of this study is to investigate the pharmacokinetic drug interaction between Solifenacin and Tamsulosin in healthy male volunteers.
- Conditions
- LUTS, Benign Prostatic Hyperplasia, Overactive Bladder
- Trial name
- NCT02447367
- Testing
- JLP-1207(Fasted), JLP-1207(Fed)
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Benign Prostatic Hyperplasia
Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
The purpose of this trial is to evaluate the dose response relationship of lonidamine and the primary efficacy endpoint, International Prostate Symptom Score (IPSS), in subjects with symptomatic benign prostatic hyperplasia (BPH).
- Trial name
- NCT00237536
- Testing
- Lonidamine
- Where
- 34 sites in United States
- Volunteers
- 240 people
- Sponsor
- Threshold Pharmaceuticals
Benign Prostatic Hyperplasia
Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System vs TURP for the Treatment of BPH
The study compares procedural and post procedural outcomes for photoselective vaporization of the prostate (PVP) and transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms due to benign…
- Trial name
- NCT01218672
- Testing
- Photoselective Vaporization of the Prostate, Transurethral Resection of the Prostate
- Where
- 29 sites in Austria, Belgium and 7 more
- Volunteers
- 291 people
- Sponsor
- Boston Scientific Corporation
BPH (Benign Prostatic Hyperplasia), HoLEP (Holmium Laser Enucleation of Prostate)
A Study of the Beacon Platform for Holmium Laser Enucleation of the Prostate (HoLEP)
This single-arm study aims to evaluate the Beacon Platform, an advancement in urological surgery. The study will assess its intraoperative and postoperative outcomes.
- Trial name
- NCT07741656
- Testing
- Beacon Platform
- Where
- 5 sites in Bulgaria, Chile and 1 more
- Volunteers
- 50 people
- Sponsor
- Andromeda Surgical
Sexual Dysfunctions in Men With Benign Prostatic Hyperplasia
Clinical Study to Assess the Influence of a Saw Palmetto Preparation in Patients With Benign Prostatic Hyperplasia (BPH) and Sexual Dysfunctions
Assessment in an open trial if a standardized saw palmetto preparation has a positive influence on sexual dysfunctions in patients with BPH and sexual dysfunctions.
- Trial name
- NCT01021267
- Testing
- Saw palmetto berry extract
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- A. Vogel AG
Benign Prostatic Hyperplasia
Assessment of Efficacy of Vardenafil in the Treatment of Subjects With Symptomatic Benign Prostatic Hyperplasia
Assessment of efficacy of vardenafil in the treatment of subjects with symptomatic Benign Prostatic Hyperplasia.The purpose of this study is to find out whether vardenafil can improve the lower urinary tract symptoms of benign…
- Trial name
- NCT00657839
- Testing
- Levitra (Vardenafil, BAY38-9456)
- Where
- 15 sites in Germany
- Volunteers
- 222 people
- Sponsor
- Bayer
Treatment of Benign Prostatic Hyperplasia
Ablation Efficacy of Contact Side Firing Fiber in Predefined Settings for Treating BPH
Twenty (20) subjects presenting with a hyperplasia enlarged prostate and candidates for surgery will undergo a single treatment for ablation of the prostate using the study device.
- Trial name
- NCT02683980
- Testing
- Lumenis Pulse P120H and Xpeeda side firing fiber
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia (BPH)
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
- Trial name
- NCT00224107
- Testing
- Silodosin
- Where
- 43 sites in United States
- Volunteers
- 461 people
- Sponsor
- Watson Pharmaceuticals
Benign Prostatic Hyperplasia
A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding.
Randomized, double-blind, placebo-controlled study with two treatment arms (Tamsulosin OCAS 0.4 mg \& placebo). The study comprises a 2-week placebo run-in followed by a 12-week treatment period.
- Trial name
- NCT00379067
- Testing
- Tamsulosin OCAS
- Volunteers
- 882 people
- Sponsor
- Astellas Pharma Inc
BPH
Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for BPH
This prospective, multicenter, two-arm, 1:1 randomized controlled trial (RCT) will enroll approximately 250 males at approximately 25 sites located within the United States.
- Trial name
- IMPACT (NCT04987892)
- Testing
- UroLift System, Tamsulosin Hydrochloride
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- NeoTract, Inc.
Prostatic Hyperplasia
Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan
This retrospective study aims to assess treatment patterns within 1 year of initiating BPH treatment, including 5-alpha-reductase inhibitor (5ARI) monotherapy, alpha-blocker (AB) monotherapy, early combination therapy, and…
- Trial name
- NCT01323998
- Testing
- 5ARI, AB
- Volunteers
- 35,032 people
- Sponsor
- GlaxoSmithKline
Benign Prostate Hypertrophy(BPH)
A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846
A Clinical trial to compare and evaluate evaluate the pharmacokinetics and safety of CKD-846
- Trial name
- NCT07404735
- Testing
- CKD-846, D091
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Prostatic Hyperplasia
Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database
Adherence and length of treatment with a 5-alpha reductase inhibitor (5ARI) therapy may be associated with improved clinical outcomes for patients with enlarged prostates (EP) and lower health care related costs.
- Trial name
- NCT01376258
- Testing
- 5ARI
- Volunteers
- 28,903 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS)
Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)
This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy of ozarelix compared to placebo in the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia…
- Trial name
- NCT00743184
- Testing
- ozarelix
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Benign Prostatic Hyperplasia
Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy
In patients with benign prostatic hyperplasia (BPH), combination therapy with an alpha-blocker (AB) and a 5 alpha-reductase inhibitor (5ARI) has been shown to reduce the progression of acute urinary retention (AUR) and the…
- Trial name
- NCT01435954
- Testing
- Early combination therapy, Delayed combination therapy
- Volunteers
- 13,551 people
- Sponsor
- GlaxoSmithKline